US Patent

US12214010 — Desmopressin oral compositions

Formulation · Assigned to Tulex Pharmaceuticals Inc · Expires 2044-04-03 · 18y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects desmopressin oral liquid formulations and methods for making and using them to treat various diseases.

USPTO Abstract

Provided herein are desmopressin oral liquid formulations. Also provided herein are methods of making and using desmopressin oral liquid compositions for the treatment of certain diseases including diabetes insipidus, enuresis, hemophilia A, von willebrand disease, high blood urea levels and others.

Drugs covered by this patent

desmopressin-acetate (DESMOPRESSIN ACETATE)

Patent Metadata

Patent number: US12214010
Jurisdiction: US
Classification: Formulation
Expires: 2044-04-03
Drug substance claim: No
Drug product claim: Yes
Assignee: Tulex Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.